Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Peer

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastasesO Sartor, D Heinrich, N Mariados, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2017
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter databaseD Keizman, M O Fosboel, H Reichegger, et al.
Blood|April 3, 2013
CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemiaOleg Fedorchenko, Marius Stiefelhagen, Abdul A Peer-Zada, et al.
Plant Biotechnology Journal|March 2, 2016
Cell wall targeted in planta iron accumulation enhances biomass conversion and seed iron concentration in Arabidopsis and riceHaibing Yang, Hui Wei, Guojie Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trialC Suarez, C Rojas, S J Shin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Nature Communications|July 7, 2015
The circadian clock rephases during lateral root organ initiation in Arabidopsis thalianaUte Voß, Michael H Wilson, Kim Kenobi, et al.
Physical Review Letters|August 26, 2022
Lawson Criterion for Ignition Exceeded in an Inertial Fusion ExperimentH Abu-Shawareb, R Acree, P Adams, et al.
Physical Review Letters|February 23, 2024
Achievement of Target Gain Larger than Unity in an Inertial Fusion ExperimentH Abu-Shawareb, R Acree, P Adams, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastasesO Sartor, D Heinrich, N Mariados, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2017
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter databaseD Keizman, M O Fosboel, H Reichegger, et al.
Blood|April 3, 2013
CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemiaOleg Fedorchenko, Marius Stiefelhagen, Abdul A Peer-Zada, et al.
Plant Biotechnology Journal|March 2, 2016
Cell wall targeted in planta iron accumulation enhances biomass conversion and seed iron concentration in Arabidopsis and riceHaibing Yang, Hui Wei, Guojie Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trialC Suarez, C Rojas, S J Shin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Nature Communications|July 7, 2015
The circadian clock rephases during lateral root organ initiation in Arabidopsis thalianaUte Voß, Michael H Wilson, Kim Kenobi, et al.
Physical Review Letters|August 26, 2022
Lawson Criterion for Ignition Exceeded in an Inertial Fusion ExperimentH Abu-Shawareb, R Acree, P Adams, et al.
Physical Review Letters|February 23, 2024
Achievement of Target Gain Larger than Unity in an Inertial Fusion ExperimentH Abu-Shawareb, R Acree, P Adams, et al.
Pageof 9